Risdiplam Tablets (Evrysdi) are an oral SMN2 splicing modifier indicated for the treatment of spinal muscular atrophy (SMA). Due to its specificity and potential risks, strict regulations must be followed for its purchase and use.

How to Purchase Risdiplam Tablets (Evrysdi)

1. Overseas Purchase

(1) Patients may choose to consult and purchase Risdiplam Tablets at hospital pharmacies or licensed retail pharmacies in countries or regions where the drug has been launched.

(2) Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

2. Purchase through Medical Service Institutions

(1) Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

(2) These institutions usually provide legal import channels and can offer professional consultation and guidance.

Precautions for Purchasing Risdiplam Tablets (Evrysdi)

1. Essential Examinations Before Medication Use

(1) Genetic Testing: Confirmation of homozygous deletion or compound heterozygous mutation of the SMN1 gene is required.

(2) Laboratory Tests: Include basic examinations such as complete blood count and liver function tests.

2. Restrictions for High-Risk Populations

(1) Contraindicated in Pregnant Women: May cause fetal malformations based on animal data; pregnancy status must be confirmed before medication use.

(2) Use with Caution in Lactating Women: No human data are available; the benefits and risks must be weighed.

(3) Abnormal Liver Function: Patients with moderate to severe hepatic impairment require careful evaluation.

3. Long-Term Monitoring Requirements

(1) Monthly Monitoring: Complete blood count and liver function.

(2) Quarterly Monitoring: Growth and development assessment.

(3) Annual Monitoring: Ophthalmic examinations (potential retinal toxicity shown in animal studies).

How to Identify the Authenticity of Risdiplam Tablets (Evrysdi)

1. Packaging Features

(1) Tablet Marking: The 5 mg tablet is a pale yellow film-coated tablet, round and curved, with "EVR" printed on one side.

(2) Solution Characteristic: When reconstituted to 80 mL, it becomes a yellowish-green to yellow solution with a concentration of 0.75 mg/mL.

(3) Manufacturing Information: The outer packaging should clearly display the manufacturer information "Genentech, Inc." and the FDA approval number.

2. Channel Verification

(1) Official Channels: Verify the batch number through the contact information provided on the drug packaging or the official website.

(2) Pharmacy Qualification: Confirm that the pharmacy has the qualification to operate special medications.

(3) Beware of Illegal Sources: Unauthorized online pharmacies and personal purchasing agents are high-risk channels.